Dogma holds that plasma cells, as opposed to B cells, cannot bind antigen because they have switched from expression of membrane-bound immunoglobulins (Ig) that constitute the B-cell receptor (BCR) to ...

IGM Biosciences IGMS, a clinical-stage company, is developing a pipeline of Immunoglobin M (IgM) antibody-based candidates to treat patients with cancer and autoimmune and inflammatory diseases. The ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies ...

How much money does a biotech need to feel comfortable in today’s market? IGM Biosciences added to evidence that the number is big after the market closed Tuesday, when it revealed a 22% reduction in ...

MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today ...

Sanofi has continued the breakneck pace of dealmaking activity, paying $150 million upfront to make IGM Biosciences the third partner added in a hectic month for its business development team. The ...

The stock market has finally dipped after a strong rally, providing a buying opportunity. The iShares Expanded Tech Sector ETF is an interesting fund and a potentially good way to buy the dip. IGM is ...

Criss Onan traces the rise and evolution of IGM, the radio automation company founded by Rogan Jones, from the 1960s to the ...